ライフサイエンスコーパス: subtilisin

1 (4) (cathepsin G) to 7.1 x 10(5) m(-1)s(-1) (subtilisin).

2 s Pronase, proteinase K, pepsin, papain, and subtilisin.

3 ease in its susceptibility to proteolysis by subtilisin.

4 avage of alphaENaC using the serine protease subtilisin.

5 tivity (4.1 microS), and were insensitive to subtilisin.

6 r throughout the main structural elements of subtilisin.

7 zing 12 amino acid positions in calcium-free subtilisin.

8 en both enzymes, while 37% were exclusive to subtilisin.

9 s targeting the serine proteases trypsin and subtilisin.

10 degrees of hydrolysis (DH) of 3-4-5-6% with subtilisin.

11 Here, we show that addition of subtilisin (50 nm to 2 mum), a serine protease secreted

12 nts but not bovine chymotrypsin or bacterial subtilisin A.

13 alysis of secretions reveals the presence of subtilisin (a protease) and a 12 kDa protein, termed sib

14 vel not significantly different from that of subtilisin activated alphaWT (125.6 +/- 23.9).

15 C-terminal peptide that may insert into the subtilisin active site.

16 Finally, subtilisin activity acted as a Th2 adjuvant to an unrela

17 l of the C-terminus of only alpha-tubulin by subtilisin after, but not before, photolabeling is block

18 Notably, subtilisin allows reproducible near-complete digestion o

19 cell-coat material is partially sensitive to subtilisin alone, while horizontal top connectors resist

20 The bacterial protease subtilisin also enhances binding by alphaXbeta2.

21 e kinetically controlled folding reaction of subtilisin, although unusual, is explained by the accrue

22 In free subtilisin, amide protons can be categorized according t

23 For example, the half-lives of subtilisin and a Bacillus subtilis lipase were increased

24 PCs are evolutionarily related to bacterial subtilisin and are synthesized as zymogens.

25 ve to calcium chelation and proteolysis with subtilisin and reappears at the tips of stereocilia as t

26 ental model of allergic lung inflammation to subtilisin and to determine the immunological mechanisms

27 Purified subtilisin and Vpr were shown to be capable of processin

28 age of the similarity of SUB1 with bacterial subtilisins and generated P. vivax SUB1 three-dimensiona

29 ophil and pancreatic elastases, cathepsin G, subtilisin, and trypsin) with a stoichiometry of inhibit

30 ions increased the half-life of calcium-free subtilisin at elevated temperature by 15,000-fold.

31 The propeptide domain of subtilisin BPN' functions as a molecular chaperone for i

32 ixed backbone design, we have redesigned the subtilisin BPN' propeptide structure to generate synthet

33 oevolved high activity and hyperstability in subtilisin by sequentially randomizing 12 amino acid pos

34 Finally, we demonstrate that subtilisin can be used for reporter-ion based in-depth q

35 examine the motion of enzyme-bound water on subtilisin Carlsberg co-lyophilized with inorganic salts

36 R spectroscopy experiments were performed on subtilisin Carlsberg colyophilized with several inorgani

37 bute to accelerated catalysis by solubilized subtilisin Carlsberg upon hydration in organic solvents.

38 The enzyme subtilisin Carlsberg was surfactant-solubilized into two

39 A limit of detection for one protease, Subtilisin carlsberg, was investigated and was establish

40 here that phosphorylation of Tyr-53 inhibits subtilisin cleavage of the D-loop and reduces the rate o

41 alphaFM were activated to similar levels by subtilisin cleavage.

42 However, subtilisin considerably improved the coverage of missing

43 olysis, immunoprecipitation experiments, and subtilisin digestion indicate that C19-BPC-discodermolid

44 e propeptide is autoprocessed and removed by subtilisin digestion.

45 methods, that the propeptide domain and the subtilisin domain show distinctive intrinsic stability t

46 ily eliminated without interference from the subtilisin domain.

47 the interface between the propeptide and the subtilisin domains play a key role in maintaining the di

48 residue propeptide at the N-terminal end of subtilisin E plays an essential role in subtilisin foldi

49 t does not inhibit serine peptidases such as subtilisin, elastase, chymotrypsin, thrombin, and plasmi

50 h the calcium chelator BAPTA or the protease subtilisin enabled these links to be further distinguish

51 e present how the broad-specificity protease subtilisin enables mapping of previously hidden areas of

52 of all plasmodia and are mapped between the subtilisin-encoding genes SUB1 and SUB3 P. berghei PIMMS

53 Subtilisin, Epr and Vpr are members of the subtilisin fa

54 the three proteases that fit these criteria, subtilisin, Epr and Vpr, had a defect in CSF production.

55 Subtilisin, Epr and Vpr are members of the subtilisin family of proteases that are widespread in ba

56 entity with fungal serine proteinases of the subtilisin family, indicating that AsES is synthesized a

57 ensitive disulphide bridge, unique among the subtilisin family, that likely acts as a regulator of pr

58 e physical nature of the kinetic barriers to subtilisin folding and to show how the prodomain overcom

59 d of subtilisin E plays an essential role in subtilisin folding as a tailor-made intramolecular chape

60 n protein folding, but its effect in slowing subtilisin folding is amplified because of the instabili

61 opeptide not only plays an essential role in subtilisin folding, but upon completion of folding it be

62 prodomain binding affects the energetics of subtilisin folding.

63 An engineered variant of the protease subtilisin from Bacillus amyloliquefaciens, in which the

64 ed phase zero introns across examined fungal subtilisin genes, half of these positions were highly co

65 Because usage of the serine protease subtilisin in the detergent industry resulted in an outb

66 ensitization followed by airway challenge to subtilisin induces prototypic allergic lung inflammation

67 ty for the generation of novel proteinaceous subtilisin inhibitors.

68 Notably, acute administration of subtilisin into the airways increased lung IL-5-producin

69 Like many secreted proteases, subtilisin is kinetically stable in the mature form but

70 These data suggest that subtilisin is the maturase for tryparedoxin peroxidases

71 Native subtilisin is thermodynamically unstable in the absence

72 Serum proprotein convertase subtilisin kexin 9 (PCSK9) binds to low-density lipoprot

73 Since the discovery of proprotein convertase subtilisin kexin 9 (PCSK9) in 2003, this PC has attracte

74 Proprotein convertase subtilisin kexin 9 (PCSK9) is a member of the subtilisin

75 glycoprotein precursor (GPC) by the cellular subtilisin kexin isozyme 1 (SKI-1)/site 1 protease (S1P)

76 The proprotein convertase subtilisin kexin isozyme 1 (SKI-1)/site 1 protease (S1P)

77 viral envelope glycoprotein by the cellular subtilisin kexin isozyme 1 (SKI-1)/site 1 protease (S1P)

78 The proprotein convertase subtilisin kexin isozyme-1 (SKI-1)/site-1 protease (S1P)

79 Subtilisin kexin isozyme-1/site-1 protease (SKI-1/S1P) p

80 (dec-RRLL-cmk), inhibitors of SKI-1 (site 1; subtilisin kexin like-1) protease.

81 ndogenous inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9) activity on cell-surface

82 poprotein B (APOB), or proprotein convertase subtilisin kexin type 9 (PCSK9) genes.

83 Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors produce incre

84 ockers, ezetimibe, and proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors, are discusse

85 Proprotein convertase subtilisin kexin type 9 (PCSK9) levels are frequently fo

86 Proprotein convertase subtilisin kexin type 9 (PCSK9) promotes the degradation

87 Levels of proprotein convertase subtilisin kexin type 9 (PCSK9) vary markedly across the

88 levels of circulating proprotein convertase subtilisin kexin type 9 (PCSK9) would increase cardiovas

89 lonal antibody against proprotein convertase subtilisin kexin type 9 (PCSK9), on Lp(a).

90 nal antibodies against proprotein convertase subtilisin kexin type 9 (PCSK9), such as evolocumab, low

91 ibody directed against proprotein convertase subtilisin kexin type 9 (PCSK9), to enable subjects at h

92 by reduced activity of proprotein convertase subtilisin kexin type 9.

93 ol-lowering drugs, the proprotein convertase subtilisin kexin-9 inhibitors.

94 inogenesis in some solid tumors, the role of subtilisin-kexin isoenzyme-1 (SKI-1) in this context is

95 antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density l

96 antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of lo

97 acologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in c

98 Proprotein convertase subtilisin-kexin type 9 (PCSK9) binds to the low-density

99 of drugs that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) has been developed to tr

100 rom clinical trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have led to c

101 nce of the efficacy of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors; however, the

102 on LDL cholesterol and proprotein convertase subtilisin-kexin type 9 (PCSK9) levels were available th

103 ibits the synthesis of proprotein convertase subtilisin-kexin type 9 (PCSK9), a target for the loweri

104 antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduc

105 nal antibody targeting proprotein convertase subtilisin-kexin type 9 (PCSK9), reduces levels of low-d

106 antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced l

107 monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9).

108 vertase site 1 protease (S1P), also known as subtilisin-kexin-isozyme 1 (SKI-1), is crucial for cell-

109 Proprotein convertase subtilisin/kexin (PCSK) enzymes convert proproteins into

110 Serum proprotein convertase subtilisin/kexin 9 (PCSK9) binds to low-density lipoprot

111 in the promoter of the proprotein convertase subtilisin/kexin 9 (PCSK9) gene that was associated with

112 efficacy and safety of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in secondary preve

113 ed that >30% of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) is bound to LDL, thus we pred

114 dy-based inhibitors of preprotein convertase subtilisin/kexin 9 (PCSK9) produce reductions in LDL-C o

115 noclonal antibodies to proprotein convertase subtilisin/kexin 9 (PCSK9) reduce LDL cholesterol in het

116 Proprotein convertase subtilisin/kexin 9 (PCSK9) regulates plasma LDL choleste

117 Proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine proteases,

118 , apolipoprotein B, or proprotein convertase subtilisin/kexin 9.

119 The proprotein convertase subtilisin/kexin enzymes proteolytically convert immatur

120 n is unique among the proprotein convertases subtilisin/kexin in being highly expressed in human GIC.

121 educed, and intestinal proprotein convertase subtilisin/kexin type 1 (Pcsk1) expression, the gene enc

122 rare mutations in the proprotein convertase subtilisin/kexin type 1 (PCSK1) gene, has been associate

123 ulated transcript, and proprotein convertase subtilisin/kexin type 1 inhibitor.

124 olymorphisms (SNPs) in proprotein convertase subtilisin/kexin type 1 with modest effects on PC1/3 in

125 Proprotein convertase subtilisin/kexin type 2 (PCSK2) is a prohormone processi

126 ies in its convertase, proprotein convertase subtilisin/kexin type 5 (PCSK5), causing inactive GDF11

127 etween ANGPTL3, furin, proprotein convertase subtilisin/kexin type 5 (PCSK5), paired amino acid conve

128 Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inducible degrader o

129 individually bind the proprotein convertase subtilisin/kexin type 9 (PCSK9) and regulate its activit

130 ntibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) are an emerging therapy

131 ction mutations of the proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with hype

132 Mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9) are strongly associated

133 an important role for proprotein convertase subtilisin/kexin type 9 (PCSK9) as a determinant of plas

134 Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds LDL receptors, tar

135 Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds low-density lipopr

136 Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors,

137 Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low-density lip

138 Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density

139 etermine the effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency on developmen

140 Proprotein convertase subtilisin/kexin type 9 (PCSK9) down-regulates surface e

141 Proprotein convertase subtilisin/kexin type 9 (PCSK9) down-regulates the low-d

142 dation mediated by the proprotein convertase subtilisin/kexin type 9 (PCSK9) has been extensively stu

143 Soluble proprotein convertase subtilisin/kexin type 9 (PCSK9) has been shown to be pre

144 Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases serum LDL-chol

145 ty and efficacy of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab in

146 The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab red

147 t use of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients w

148 Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors substantially

149 Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were recently

150 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the prote

151 l antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new lipid-lowering

152 The secreted protein proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new targe

153 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein th

154 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important factor i

155 Do elevated proprotein convertase subtilisin/kexin type 9 (PCSK9) levels constitute an eve

156 in receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) messenger ribonucleic ac

157 Proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates low-density li

158 Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regu

159 Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role

160 Proprotein convertase subtilisin/kexin type 9 (PCSK9) posttranslationally regu

161 e the LDL-ApoB-100 and proprotein convertase subtilisin/kexin type 9 (PCSK9) production rate (PR) and

162 Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes degradation of

163 The proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes independently o

164 Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low density li

165 Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low density li

166 Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates serum LDL chol

167 Proprotein convertase subtilisin/kexin type 9 (PCSK9) selectively binds low-de

168 lonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) serine protease, demonst

169 strategies to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) show promise as anti-hyp

170 Mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9) that are associated with

171 its negative regulator proprotein convertase subtilisin/kexin type 9 (PCSK9) through the first EGF (e

172 Proprotein convertase subtilisin/kexin type 9 (PCSK9) was shown to have a mutu

173 antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein t

174 Proprotein convertase subtilisin/kexin type 9 (PCSK9), a member of the protein

175 t ENaC is regulated by proprotein convertase subtilisin/kexin type 9 (PCSK9), a protease that modulat

176 ated the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that facilita

177 presence of exogenous proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces

178 olipoprotein B (APOB), proprotein convertase subtilisin/kexin type 9 (PCSK9), and LDL protein recepto

179 mutations in the apoB, proprotein convertase subtilisin/kexin type 9 (PCSK9), and MTP genes result in

180 monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), demonstrated marked red

181 ntibodies that bind to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowering LDL by about 5

182 monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), lowers plasma low-densi

183 monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), reduced LDL cholesterol

184 antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced l

185 lonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced l

186 lonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced L

187 l antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).

188 lonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9).

189 Importantly, reduced proprotein convertase subtilisin/kexin type 9 activity increases recycling of

190 g activity using human proprotein convertase subtilisin/kexin type 9 and platelet factor-4, whereas t

191 Plasma proprotein convertase subtilisin/kexin type 9 and total cholesterol increased

192 Using proprotein convertase subtilisin/kexin type 9 as a representative protein targ

193 ascular pathology in a proprotein convertase subtilisin/kexin type 9 gain-of-function atherosclerosis

194 quence variants in the proprotein convertase subtilisin/kexin type 9 gene (PCSK9) lower plasma low-de

195 ectiveness analyses of proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) were based on

196 The proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab has been de

197 95% CI, 0.58-0.65) for proprotein convertase subtilisin/kexin type 9 inhibitors (P = .25).

198 Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are a novel

199 ining lipoproteins and proprotein convertase subtilisin/kexin type 9 inhibitors hold promise in reduc

200 Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies can reduce

201 ncode gain-of-function proprotein convertase subtilisin/kexin type 9 mutants, and mice were given a s

202 erol, campesterol, and proprotein convertase subtilisin/kexin type 9 plasma concentrations and fatty

203 noclonal antibodies to proprotein convertase subtilisin/kexin type 9 published in the last 18 months

204 Inhibition of proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) resulted

205 sense mutations in the proprotein convertase subtilisin/kexin type 9 serine protease gene (PCSK9) cau

206 quence variants in the proprotein convertase subtilisin/kexin type 9 serine protease gene (PCSK9) tha

207 ve data that targeting proprotein convertase subtilisin/kexin type 9 very effectively reduces LDL-cho

208 utations within PCSK9 (proprotein convertase subtilisin/kexin type 9) are associated with dominant fo

209 has identified PCSK9 (proprotein convertase subtilisin/kexin type 9) as a crucial gene in the regula

210 targeting human PCSK9 (proprotein convertase subtilisin/kexin type 9) as an alternative to anti-PCSK9

211 PCSK9 (proprotein convertase subtilisin/kexin type 9) has emerged as a novel therapeu

212 PCSK9 (proprotein convertase subtilisin/kexin type 9) has emerged as an important reg

213 The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced lo

214 PCSK9 (proprotein convertase subtilisin/kexin type 9) is a negative regulator of the

215 nal antibody to PCSK9 (proprotein convertase subtilisin/kexin type 9), markedly reduces low-density l

216 noclonal antibodies to proprotein convertase subtilisin/kexin type 9, cholesterol ester transfer prot

217 achieved by inhibiting proprotein convertase subtilisin/kexin type 9, may decrease the systemic infla

218 Single injections of proprotein convertase subtilisin/kexin type 9-encoding recombinant adeno-assoc

219 PCSK9 encodes proprotein convertase subtilisin/kexin type 9a (PCSK9), a member of the protei

220 Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a secreted protein th

221 Proprotein convertase subtilisin/kexin type-9 (PCSK9, a hepatic LDL-receptor r

222 pharmacological PCSK9 (proprotein convertase subtilisin/kexin type-9) inhibition was not associated w

223 The archetype proprotein convertase subtilisin/kexin, FURIN, is a direct target gene of the

224 Here we show that proprotein convertase subtilisin/kexin-6 (PCSK6, also named PACE4;) cleaves an

225 Recently approved proprotein convertase subtilisin/kexin-type 9 inhibitors and mipomersen lower

226 of the family of the proprotein convertases subtilisin/kexin.

227 lthough effects of the proprotein convertase subtilisin/kexine type 9 gene (PCSK9) need fuller explor

228 F-A domain resides on the surface of PCSK9's subtilisin-like catalytic domain containing Asp-374, a r

229 acid residues corresponding to the putative subtilisin-like catalytic triad are important but not es

230 chanism and structural characterization of a subtilisin-like collagenolytic protease secreted by a de

231 Here, a novel subtilisin-like collagenolytic protease, myroicolsin, wh

232 We conclude that glycoprotein cleavage by subtilisin-like endoproteases is not critical for Ebola

233 chonia chlamydosporia belongs to a family of subtilisin-like enzymes that are involved in infection o

234 cture of MycP1(24-407) to 1.86 A, defining a subtilisin-like fold with a unique N-terminal extension

235 serine proteases, a group characterized by a subtilisin-like fold, a Ser-Glu-Asp catalytic triad, and

236 ithelial expression of proprotein convertase subtilisin-like kexin type 9, a key regulator of cholest

237 lipoprotein B-100, and proprotein convertase subtilisin-like kexin type 9.

238 olipoprotein B-100 and proprotein convertase subtilisin-like kexin type 9.

239 -islet cells and is processed in parallel by subtilisin-like prohormone convertases prior to secretio

240 rotein convertase 7 (PC7) is a member of the subtilisin-like proprotein convertase family, which is i

241 motes FGF23 cleavage and inactivation by the subtilisin-like proprotein convertase furin.

242 0), within the FGF23 R(176)XXR(179)/S(180)AE subtilisin-like proprotein convertase motif.

243 Subtilisin-like proprotein convertases (SPCs) are a fami

244 inactive precursor molecules by a family of subtilisin-like proprotein convertases (SPCs).

245 was found to be derived from a member of the subtilisin-like protease (subtilase) family.

246 We previously showed that a subtilisin-like protease called PfSUB1 regulates egress

247 The subtilisin-like protease P69B was identified as a substr

248 nclude ABNORMAL LEAF SHAPE1, which encodes a subtilisin-like protease previously shown to have a simi

249 Subtilisin-like proteases and other pathogenesis-related

250 identity (<30%) to previously characterized subtilisin-like proteases, and it contains a novel domai

251 s are mediated respectively, by two parasite subtilisin-like proteases, PfSUB1 and PfSUB2, but the fu

252 ghei protein with structural similarities to subtilisin-like proteins.

253 E activity in seed coat epidermal cells, the subtilisin-like Ser protease SBT1.7, acts on different P

254 lt stress response in Arabidopsis requires a subtilisin-like serine protease (AtS1P), related to mamm

255 on site for site-1 protease (AtS1P), a plant subtilisin-like serine protease (subtilase).

256 dress this issue we have concentrated on the subtilisin-like serine protease encoding gene ABNORMAL L

257 d inhibit the pathogenesis-related (PR) P69B subtilisin-like serine protease of tomato.

258 and invasion, controlling maturation of the subtilisin-like serine protease SUB1 in exoneme secretor

259 The essential subtilisin-like serine protease SUB1 of Plasmodium meroz

260 ng of proAtPSK4 was dependent on AtSBT1.1, a subtilisin-like serine protease, encoded by one of 56 su

261 Subtilisin-like serine proteases (SBTs) are extracellula

262 The propeptides of subtilisin-like serine proteinases (subtilases, SBTs) se

263 Instead, a subtilisin-like serine-dependent plant protease named ph

264 convertases (PCs) comprise a large family of subtilisin-like, eukaryotic, serine endoproteases that p

265 PCSK9 (proprotein convertase subtilisin-like/kexin type 9) is an emerging target for

266 sidues, Trp106 and Trp113, on the surface of subtilisin located on one of the two helices that form t

267 Thus, subtilisin might be particularly beneficial for system-w

268 of the subtilisin prodomain and a series of subtilisin mutants, which were designed to explore the s

269 ll wall material, or the processing protease subtilisin or Vpr.

270 died the bimolecular folding reaction of the subtilisin prodomain and a series of subtilisin mutants,

271 resonance (NMR), revealing that it mimics a subtilisin prodomain including a flexible C-terminal pep

272 The substrate is based on a stabilized subtilisin prodomain, extended across the active site by

273 Below a threshold concentration, subtilisin promotes colony growth and expansion.

274 Purified subtilisin promotes the growth and expansion of P. dendr

275 t the identification and characterization of subtilisin propeptide-like inhibitor 1 (SPI-1) from Arab

276 Gbb and Scw have three functional furin/subtilisin proprotein convertase cleavage sites; two bet

277 that undergo proteolytic processing by furin/subtilisin proprotein convertases to release the active

278 The subtilisin protease (SUB; Clan SB, family S8) of Leishma

279 These allergic responses were dependent on subtilisin protease activity, protease-activated recepto

280 The subtilisin protease TgSUB1 trims several MICs on the par

281 Like subtilisin proteases in other Apicomplexan parasites, Bd

282 tely 80-kDa passenger domain that contains a subtilisin-related domain.

283 onserved regions in a multigene family of 56 subtilisin-related proteolytic enzymes in Arabidopsis th

284 ed and found to be inactive, but exposure to subtilisin resulted in cleavage to the active, 12 kDa fo

285 rdinately slow folding of the mature form of subtilisin results from the accrued effects of two slow

286 t folding intermediates results in part from subtilisin's high dependence on metal binding for stabil

287 vide extensive information for understanding subtilisin's substrate binding and catalytic mechanism,

288 mediate as well as why the unfolding of free subtilisin seldom occurs via this intermediate.

289 ubtilisin kexin 9 (PCSK9) is a member of the subtilisin serine protease family with an important role

290 mbined with mathematical modeling, show that subtilisin serves to regulate growth of the colony.

291 Also, subtilisin stimulated the expression of the proallergic

292 ene product (BdSUB-1) clearly belongs to the subtilisin superfamily and shows significant homology to

293 well studied endopeptidases belonging to the subtilisin superfamily.

294 at purified StmPr1 behaves more similarly to subtilisin than to trypsin.

295 thways involved in allergic sensitization to subtilisin that potentially contribute to initiate aller

296 our knowledge, the first report of a fungal subtilisin that shows eliciting activity in plants.

297 yl peptidases have a fold resembling that of subtilisin, the proton transfer processes during the nuc

298 haFD retained the ability to be activated by subtilisin to 108.8 +/- 20.9 microS, a level not signifi

299 mide protons in free and prodomain-complexed subtilisin were determined in order to understand how th

300 and shows significant homology to Plasmodium subtilisins, with the highest degree of sequence identit